{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:24:58Z","timestamp":1783441498539,"version":"3.54.6"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Normocalcemic primary hyperparathyroidism (NHPT) is considered to be an early stage in the evolution of primary hyperparathyroidism (PHPT). To formulate a correct diagnosis, secondary hyperparathyroidism due to low calcium intake must be excluded. Whether dietary calcium intake might affect the clinical presentation of PHPT or NHPT has never been addressed consistently.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe patients with a diagnosis of NHPT or PHPT in relation to their calcium intake, through three standard validated questionnaires; to describe clinical, biochemical and radiological features of NHPT and PHPT patients compared to each other and to a control group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Cross-sectional study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Outpatient, single academic medical center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>109 consecutive women recruited from February 2021 through April 2023. 54 patients with mild primary hyperparathyroidism (PHPT or NHPT) were age-matched with 55 unselected women undergoing bone density test screening due to recently diagnosed hormone-positive breast cancer. NHPT diagnosis was based on multiple determinations of both total and albumin-corrected serum calcium.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Administration of all the following during routine endocrine consultation: a country-specific food-frequency questionnaire (LOC), the International Osteoporosis Foundation Calcium Calculator (IOF) and the National Osteoporosis Foundation calcium questionnaire (NOF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Any association between dietary calcium intake and clinical, radiological, or biochemical features.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All three questionnaires confirmed that NHPT patients had similar calcium intake as those with PHPT or controls. Biochemistries and bone turnover markers were similar between the two variants of hyperparathyroidism, except for serum calcium (sCa). NHPT patients had a significantly lower BMD and T-score at one-third distal radius compared to PHPT, while the prevalence of nephrolithiasis and clinical fractures were similar. Multivariate analysis investigating predictors of serum calcium showed that age, eGFR, calcium intake and 25(OH)D did not significantly affect serum calcium, while multivariate analysis investigating predictors of PTH (age, variant NHPT vs. PHPT, eGFR, calcium intake, 25(OH)D, cholecalciferol supplements) showed that calcium intake, variant and renal function, significantly influenced PTH levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>All patients with primary hyperparathyroidism, particularly those with low dietary calcium intake, should be advised not to restrict dietary calcium to prevent further increase in PTH levels. Whether maintaining adequate calcium intake might positively impact bone density or biochemistries in patients refraining from surgery, should be addressed in longitudinal studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1428640","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:11:57Z","timestamp":1738559517000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Dietary calcium intake in primary hyperparathyroidism and in its normocalcemic variant: a case-control study"],"prefix":"10.3389","volume":"15","author":[{"given":"Nicol\u00f2","family":"Bisceglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Malagrin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Vandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Repaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uberto","family":"Pagotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Zavatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1210\/jc.2018-01225","article-title":"Primary hyperparathyroidism","volume":"103","author":"Bilezikian","year":"2018","journal-title":"J Clin Endocrinol Metab [Internet]."},{"key":"B2","article-title":"Evaluation and management of primary hyperparathyroidism: Summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Mineral Res John Wiley Sons Inc;"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1210\/jcem-67-6-1294","article-title":"Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: Evidence for biphasic disease course","volume":"67","author":"Rao","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2003-031014","article-title":"\"Incipient\" primary hyperparathyroidism: A \"Forme fruste\" of an old disease","volume":"88","author":"Silverberg","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10391","article-title":"Normocalcemic hyperparathyroidism: A heterogeneous disorder often misdiagnosed","volume":"4","author":"Zavatta","year":"2020","journal-title":"JBMR Plus"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-016-3716-2","article-title":"Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. a canadian and international consensus","volume":"28","author":"Khan","year":"2017","journal-title":"Osteoporosis Int"},{"key":"B7","article-title":"Normocalcemic primary hyperparathyroidism","volume":"66","author":"Cusano","year":"2022","journal-title":"Arch Endocrinol Metab Sociedade Bras Endocrinologia e Metabologia;"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad013","article-title":"The eucalcemic patient with elevated parathyroid hormone levels","volume":"7","author":"Shaker","year":"2023","journal-title":"J Endocr Soc"},{"key":"B9","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders (PARAT 2021)","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur J Endocrinology. BioScientifica Ltd."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae074\/7685659","article-title":"Natural history and complications of normocalcemic hyperparathyroidism: a retrospective 2 cohort study","author":"Wei","year":""},{"key":"B11","article-title":"Normocalcemic hyperparathyroidism: Study of its prevalence and natural history","volume":"105","author":"Schini","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM198510313131805","article-title":"Sensitivity of the parathyroid hormone-1,25-dihydroxyvitamin d axis to variations in calcium intake in patients with primary hyperparathyroidism","volume":"313","author":"Insogna","year":"1985","journal-title":"N Engl J Med"},{"key":"B13","article-title":"Optimal dietary calcium intake in primary hyperparathyroidism","volume":"102","author":"Gartenberg","year":"1997","journal-title":"Am J Med by Excerpta Medica Inc"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1007\/s00394-002-0383-1","article-title":"The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake","volume":"41","author":"Jorde","year":"2002","journal-title":"Eur J Nutr"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI108696","article-title":"The role of 1 alpha, 25-dihydroxyvitamin d in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria","volume":"59","author":"Kaplan","year":"1977","journal-title":"J Clin Invest."},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM198002213020801","article-title":"The importance of circulating 1,25-dihydroxyvitamin d in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism","volume":"302","author":"Broadus","year":"1980","journal-title":"N Engl J Med"},{"key":"B17","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin d from the institute of medicine: What clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab Endocrine Society;"},{"key":"B18","article-title":"Calcium intake and risk of primary hyperparathyroidism in women: Prospective cohort study","volume":"345","author":"Paik","year":"2012","journal-title":"BMJ (Online)"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1038\/bonekey.2013.48","article-title":"Does calcium intake influence the development of primary hyperparathyroidism","volume":"10","author":"Chiavistelli","year":"2013","journal-title":"IBMS Bonekey"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1210\/jcem-48-6-1008","article-title":"The effects of oral CaCO3 loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin d concentrations in healthy adults","volume":"48","author":"Adams","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2007.10.003","article-title":"Relationship between serum parathyroid hormone, vitamin d sufficiency, age, and calcium intake","volume":"42","author":"Adami","year":"2008","journal-title":"Bone"},{"key":"B22","article-title":"Medical management of primary hyperparathyroidism: Proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism","volume":"99","author":"Marcocci","year":"2014","journal-title":"J Clin Endocrinol Metab [Internet]."},{"key":"B23","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop","volume":"94","author":"Bilezikian","year":"2009","journal-title":"J Clin Endocrinol Metab [Internet]"},{"key":"B24","unstructured":""},{"key":"B25","doi-asserted-by":"crossref","unstructured":"ORIGINAL COMMUNICATION Validation of a food frequency questionnaire for nutritional calcium intake assessment in Italian women\n          \n          \n            \n              Montomoli\n              M\n            \n            \n              Gonnelli\n              S\n            \n            \n              Giacchi\n              M\n            \n            \n              Mattei\n              R\n            \n            \n              Cuda\n              C\n            \n            \n              Rossi\n              S\n            \n          \n          Eur J Clin Nutr [Internet]\n          56\n          2002","DOI":"10.1038\/sj.ejcn.1601278"},{"key":"B26","unstructured":""},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqad189","article-title":"Role of vitamin D and calcium nutrition in sporadic parathyroid tumorigenesis: Clinical Implications and future research","author":"Rao","year":"2023","journal-title":"Endocrinology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2021.1061","article-title":"Normocalcemic primary hyperparathyroidism: need for a standardized clinical approach","volume":"36","author":"Zavatta","year":"2021","journal-title":"Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4230-x","article-title":"Global dietary calcium intake among adults: a systematic review","author":"Balk","year":""},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa174","article-title":"Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism","volume":"105","author":"Palermo","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2014-3708","article-title":"Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology","volume":"100","author":"Cipriani","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2011-0569","article-title":"Nephrolithiasis and renal calcifications in primary hyperparathyroidism","volume":"96","author":"Rejnmark","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.10.1700","article-title":"Primary hyperparathyroidism and the risk of fracture: a population-based study","volume":"14","author":"Khosla","year":"1999","journal-title":"J Bone Miner Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2006","article-title":"Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism","volume":"94","author":"Vignali","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02276-7","article-title":"The calcium-to-phosphorous (Ca\/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study","volume":"68","author":"Madeo","year":"2020","journal-title":"Endocrine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4158\/EP151055.OR","article-title":"Trabecular bone score in patients with normocalcemic hyperparathyroidism","volume":"22","author":"D\u00edaz-Soto","year":"2016","journal-title":"Endocr Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-018-4512-2","article-title":"Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ","volume":"42","author":"Kiriakopoulos","year":"2018","journal-title":"World J Surg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-015-0673-3","article-title":"Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism","volume":"34","author":"M\u00fcsl\u00fcm Tuna","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2802","article-title":"Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype","volume":"92","author":"Lowe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","unstructured":"Bone Mineral Density Evolution After Successful Parathyroidectomy in Patients With Normocalcemic Primary Hyperparathyroidism\n          \n          \n            \n              Koumakis\n              E\n            \n            \n              Souberbielle\n              JC\n            \n            \n              Sarfati\n              E\n            \n            \n              Meunier\n              M\n            \n            \n              Maury\n              E\n            \n            \n              Gallimard\n              E\n            \n          \n          \n          2013"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000198","article-title":"An overview of normocalcemic primary hyperparathyroidism","volume":"22","author":"Pawlowska","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B42","unstructured":"Normocalcemic Primary Hyperparathyroidism: Evidence for a Generalized Target-Tissue Resistance to Parathyroid Hormone\n          \n          \n            \n              Rard Maruani\n              G\n            \n            \n              Hertig\n              A\n            \n            \n              Paillard\n              M\n            \n            \n              Houillier\n              P\n            \n          \n          \n          2003"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/128352","article-title":"Clinical Study Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More Stone than Bone","volume":"2012","author":"Amaral","year":"2012","journal-title":"J Osteoporos"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1428640\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:12:08Z","timestamp":1738559528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1428640\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":43,"alternative-id":["10.3389\/fendo.2024.1428640"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1428640","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"article-number":"1428640"}}